LAST CHANCE to register for the IASLC 2020 Targeted Therapies in Lung Cancer Meeting (to be held THIS WEEK February 17-20). The program is a series of 5-minute presentations on lab research and clinical trials for targeted therapies. The session on ALK & ROS1 inhibitors happens on Thursday February 18 at 14:40 Eastern Time. This … Continue reading Last Chance to register for @IASLC #TTLC21
Many ROS1ders have expressed an interest in attending a virtual meet-up via Zoom for ROS1 patients and caregivers. Now it’s going to happen! The two co-hosts Renee Parker, MD, and Janet Lathan (ROS1 patients and members of the ROS1ders) will facilitate informal ROS1der MeetUps via Zoom twice monthly starting Tuesday, 11/10/2020 on the following dates: … Continue reading Please join us for informal ROS1der MEETUPS!
The newest issue of ROS1derings, the newsletter of The ROS1ders, is out. You can access the pdf file using the link below. Enjoy! ROS1derings Issue 4 (August 2020)
Two independent studies found ROS1+ lung cancer patients are more likely to develop blood clots than patients who have other lung cancers. Pulmonary embolisms are not uncommon in the ROS1ders, and these types of blood clots can eventually result in pulmonary hypertension (because it increases pressure on the heart). The appearance of a new blood … Continue reading Pulmonary hypertension in ROS1+ patients on TKIs
For the first time, Australian ROS1+ lung cancer patients may have affordable access to Entrectnib. Currently, ROS1 patients cannot get access to Entrectnib outside of a clinical trial. We need the help of ROS1ders to make it happen. From 1 February 2020, Australian who have ROS1+ lung cancer may be able to purchase the medication … Continue reading Calling all ROS1ders! Please help Australians access Entrectinib
Lung Cancer Canada (LCC) is seeking ROS1 positive non-small cell lung cancer (NSCLC) patients and caregivers who have past or present treatment experience with ENTRECTINIB to share their experiences. This information will be used to provide patient/caregiver input that will help in determining accessibility of this drug for lung cancer patients in Canada. LCC and … Continue reading ROS1DERS: You can help Canadian ROS1+ NSCLC patients gain access to entrectinib!